Back to Search
Start Over
Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.
- Source :
-
Clinical journal of gastroenterology [Clin J Gastroenterol] 2020 Jun; Vol. 13 (3), pp. 344-348. Date of Electronic Publication: 2019 Oct 14. - Publication Year :
- 2020
-
Abstract
- Secondary thrombotic microangiopathy (TMA) can be induced by several underlying conditions and drugs, yet coexistence of TMA and inflammatory bowel disease (IBD) has only infrequently been documented. A successful management beyond supportive care in cases with secondary TMA represents a challenge, as some underlying conditions might amplify complement dysregulation or even unmask a genetic predisposition to atypical hemolytic uremic syndrome (HUS)-both of which could require treatment with a complement blocking agent. We observed a case in which TMA developed in a patient with ulcerative colitis (UC). Genetic screening showed a heterozygous mutation in diacylglycerol kinase ε (DGKE). Eculizumab resulted in complete resolution of TMA, however UC relapsed after cessation of eculizumab.
- Subjects :
- Adult
Atypical Hemolytic Uremic Syndrome drug therapy
Atypical Hemolytic Uremic Syndrome etiology
Atypical Hemolytic Uremic Syndrome genetics
Diacylglycerol Kinase genetics
Female
Humans
Thrombotic Microangiopathies drug therapy
Antibodies, Monoclonal, Humanized therapeutic use
Colitis, Ulcerative complications
Complement Inactivating Agents therapeutic use
Thrombotic Microangiopathies etiology
Subjects
Details
- Language :
- English
- ISSN :
- 1865-7265
- Volume :
- 13
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Clinical journal of gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- 31612381
- Full Text :
- https://doi.org/10.1007/s12328-019-01052-z